menu
    • menu
    [{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ACE-083","moa":"GDF8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept-aamt","moa":"TGF beta","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Acceleron Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ACE-1334","moa":"TGF beta-2","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Acceleron Pharma Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Acceleron Pharma Inc."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":11.5,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Merck"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":11.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":11.5,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Acceleron Pharma \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Merck"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acceleron Pharma \/ Acceleron Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acceleron Pharma \/ Acceleron Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Acceleron Pharma

    Menu

    Acceleron Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-...

                            Details : Reblozyl (luspatercept-aamt) first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models, is currently approved in the U.S. for treatment of anemia in adult patients with beta thalassemia who require regular red bloo...

                            Brand Name : Reblozyl

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 03, 2022

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Merck

                            Deal Size : $11,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Completes Acquisition of Acceleron Pharma Inc.

                            Details : Through the successful completion of the acquisition of Acceleron Pharma, Merck would be growing its cardiovascular portfolio and pipeline, including Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potentia...

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : $11,500.0 million

                            November 19, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Merck

                            Deal Size : $11,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $11,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck to Acquire Acceleron Pharma Inc

                            Details : Under the terms of the acquisition agreement, Merck will acquire all outstanding shares of Acceleron including its pipeline having lead therapeutic candidate, sotatercept, in Phase 3 trials as add-on to current standard of care for the treatment of PAH.

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : $11,500.0 million

                            September 30, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $11,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept...

                            Details : Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo. Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a contin...

                            Brand Name : Reblozyl

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 11, 2021

                            Lead Product(s) : Luspatercept

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypert...

                            Details : The SPECTRA Phase 2 trial is a single arm, open-label, multi-center exploratory study to determine the eects of sotatercept plus standard of care in adults with WHO functional class III PAH.

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 19, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceleron Presents Interim Results from Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Pul...

                            Details : A total of 106 patients were randomized in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg subcutaneously every three weeks on top of standard-of-care therapies.

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 19, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceleron to Host Conference Call and Webcast to Review Trial Updates, Preclinical Presentations on Sotatercep...

                            Details : The PULSAR Phase 2 trial evaluating sotatercept in combination with approved PAH-specific medicines in patients with PAH achieved its primary endpoint of improvement in pulmonary vascular resistance and its key secondary endpoint of improvement in 6-minu...

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 11, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NEJM Publishes Results of Acceleron's Pulsar Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial ...

                            Details : Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo.

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 01, 2021

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial ...

                            Details : Acceleron is currently advancing a Phase 3 development plan for sotatercept, beginning with the registrational trial known as STELLAR expected to initiate by the end of this year.

                            Brand Name : ACE-011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 14, 2020

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Acceleron Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACE-1334

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis

                            Details : ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Acceleron plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease in ...

                            Brand Name : ACE-1334

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            December 01, 2020

                            Lead Product(s) : ACE-1334

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth